Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Manali A. Bhave, Komal L. Jhaveri, Peter A. Kaufman, Philippe Georges Aftimos, Janine Margaret Lombard, Kostandinos Sideras, Seock-Ah Im, Cynthia X. Ma, Kuo-Ting Lee, Sung-Bae Kim, Yujia Li, Eunice Yuen, Shawn T. Estrem, Bastien Nguyen, Francesca Bacchion, Roohi Ismail-Khan, Muralidhar Beeram, Joohyuk Sohn
Institutions: Emory University, Memorial Sloan Kettering Cancer Center, University of Vermont, University of Vermont Medical Center, Université Libre de Bruxelles, Institut Jules Bordet, Calvary Mater Newcastle Hospital, Mayo Clinic in Florida, Seoul National University, Seoul National University Hospital, Washington University in St. Louis, National Cheng Kung University Hospital, Asan Medical Center, University of Ulsan, Eli Lilly (United States), South Texas Accelerated Research Therapeutics, Severance Hospital, Yonsei University Health System
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W4399323625